Navigation Links
INVEGA® Approved as Treatment for Schizophrenia in Adolescents
Date:4/11/2011

ditions that would predispose patients to hypotension (e.g., dehydration, hypovolemia, treatment with anti-hypertensive medications). Monitoring should be considered in patients who are vulnerable to hypotension.

Leukopenia, Neutropenia and Agranulocytosis have been reported with antipsychotics, including paliperidone. Patients with a history of clinically significant low white blood cell count (WBC) or drug-induced leukopenia/neutropenia should have frequent complete blood cell counts during the first few months of therapy. At the first sign of a clinically significant decline in WBC, and in the absence of other causative factors, discontinuation of INVEGA® should be considered. Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm3) should discontinue INVEGA® and have their WBC followed until recovery.

Potential for Cognitive and Motor Impairment: Somnolence was reported in subjects treated with INVEGA®. INVEGA® has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about performing activities that require mental alertness such as operating hazardous machinery, including motor vehicles, until they are reasonably certain that INVEGA® does not adversely affect them.

Seizures: INVEGA® should be used cautiously in patients with a history of seizures or with conditions that potentially lower seizure threshold. Conditions that lower seizure threshold may be more prevalent in patients 65 years or older.

Suicide: The possibility of suicide attempt is inherent in psychotic illnesses. Close supervision of high-risk patients should accompany drug therapy. Prescriptions should be written for the smallest quantity of tablets to reduce the risk of overdose.

Commonly Observed A
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA®
2. FDA CONSUMER HEALTH INFORMATION - FDA Intends to Remove Unapproved Drugs From Market
3. FDA Prompts Removal of Unapproved Drugs From Market
4. Roche Teams with Womack Army Medical Center to Become First IVD Manufacturer approved for Remote Network Connectivity with DOD
5. DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product
6. FDA: Gardasil Approved to Prevent Anal Cancer
7. CO-REC Unveils List of Approved Electronic Health Record Products
8. Bionovo Releases FDA-Approved Clinical Development Plan for Menerba
9. A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity
10. Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs
11. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
(Date:7/10/2014)... 10, 2014   LabStyle Innovations Corp . ... announced the appointment of Professor Richard B. ... Board of Directors. Prof. Stone brings ... to LabStyle as an entrepreneur, venture capitalist public, ... governance expert. He currently serves on the board ...
(Date:7/10/2014)... -- Decision Resources Group finds that over half of ... Drug Administration,s (FDA) approval of Vifor Fresenius Medical Care ... by the FDA in November 2013 for the treatment ... dialysis. Other key findings from the report ... : , Bundling: Based ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... Study) Results Demonstrate ... of VH(R) IVUS in Drug Development, SAN DIEGO, ... [ESC Booth # A2-D403], a leading manufacturer of,intravascular ultrasound ... of its VH(R) IVUS (Virtual Histology IVUS) in,GlaxoSmithKline,s IBIS-2 ...
... 1 Calabar AB, a privately,held pharmaceutical company ... EUR 350,000 equity financing from the investment company,Karolinska ... a phase II study with repeated dosing. "We ... the minor glands will lead to improved outcomes ...
Cached Medicine Technology:Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 2Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 3Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 4
(Date:7/10/2014)... 10, 2014 One week ahead of ... Safety announced today it will extend compensation benefits to ... wages for workers displaced as a result of factory ... inspections have resulted in the closure of five factories ... cases, raising immediate safety concerns. In May, the Alliance—in ...
(Date:7/10/2014)... NY (PRWEB) July 10, 2014 CBPartners, ... sciences industry, has launched a new website. The ... well as increased access to the firm’s thought pieces, ... provides an ideal platform to showcase our insights, capabilities, ... issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
(Date:7/10/2014)... A new study from Colorado School of Public ... health remains a major problem in the Navajo Nation ... among Native Americans is abysmal with more than three ... said Terrence Batliner, DDS, MBA, associate director of the ... of Public Health. "The number one problem is access ...
(Date:7/10/2014)... News) -- Most professional football players who have shoulder ... a new study finds. Shoulder instability is a ... return after surgery to fix the problem has been ... included 60 players who had shoulder stabilization surgery. Ninety ... to play, defined as playing in at least one ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:CBPartners Announces New Website 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Shoulder Surgery Gets NFL Players Back in the Game 2
... Lee, M.D., breast cancer researcher and assistant member ... grant from General Electric,s $100 million healthymagination Challenge ... genetic makeup to determine if they are predisposed ... GE,s healthymagination grant awarding initiative focuses on "finding ...
... Five Indiana University School of Medicine geriatricians are ... nationwide who will share in $2.5 million in career ... IU School of Medicine was one of the top-funded ... Medicine are: , Tochukwu Iloabuchi, M.D., advanced geriatrics ...
... H. Julia Hannay, the John and Rebecca Moores Professor ... 2012 Ester Farfel Award, a symbol of overall career ... faculty member. The annual award carries a cash prize ... honor recognizing the many roles that we may have ...
... Electrocardiograph (EKG) screening of young athletes can help identify those ... study. Researchers screened nearly more than 1,300 young athletes ... history, family history, a physical exam or prior EKG. Six ... cause sudden cardiac death. The study looked at how ...
... public health threats, early diagnosis of infectious diseases is ... globe where conventional medical tools like microscopes and cytometers ... to make disease screening quicker and simpler. ... or fluid samples are placed. Specific changes in the ...
... of small molecules that kill cancer cells caused by ... both cell and mouse models, demonstrate that the small ... proteins, thus killing the infected tumor cells. The ... issue of the journal Chemistry & Biology . ...
Cached Medicine News:Health News:Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks 2Health News:Awards to 5 IU School of Medicine physicians address critical need for geriatricians 2Health News:Neuropsychologist receives University of Houston's highest faculty honor 2Health News:Neuropsychologist receives University of Houston's highest faculty honor 3Health News:Heart Test Spots Sudden Death Risk in Young Athletes 2Health News:UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity 2Health News:UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity 3Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: